01—Abstract
Summary
Summary of the 8-K filed August 1, 2024. Cited figures are marked; the original filing is the authoritative source.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported its financial results for the second quarter ended June 30, 2024, and an operational update in a press release furnished as Exhibit 99.1 to this Form 8-K.
Revenue was $2.2 milliona for the three months ended June 30, 2024 and $213.3 million for the six months, compared with $1.6 million and $3.5 million in the prior-year periods. The six-month increase was primarily driven by $202.9 million of non-refundable upfront payments and service revenue under the Bayer and Kyowa Kirin exclusive license and collaboration agreements. Net loss attributable to common stockholders of BridgeBio was $73.5 million for the quarter ($0.39 per share), compared with $157.9 million ($0.98 per share) a year earlier, and $108.7 million for the six months ($0.59 per share).
The quarterly result benefited from a $126.3 millionb gain on deconsolidation of a subsidiary. Cash, cash equivalents, marketable securities and short-term restricted cash totaled $587.2 million at June 30, 2024, up from $392.6 million at December 31, 2023, reflecting $434.0 million of net term loan proceeds from Blue Owl and $314.8 million of net equity financing proceeds, partly offset by $473.4 million used to refinance the prior senior secured term loan and $144.8 million of operating cash outflow for the six months. On the pipeline, the company highlighted that the NDA for acoramidis for ATTR-CM has a PDUFA date of November 29, 2024, and that new analyses presented at the 2024 ISA and ESC-HF Congress included a statistically significant reduction in all-cause mortality (p=0.04) in the intention-to-treat population of ATTRibute-CM.
Low-dose infigratinib in Cohort 5 of PROPEL 2 showed a statistically significant increase in annualized height velocity of +2.50 cm/yr at Month 18 (p=0.0015). BridgeBio surpassed the interim analysis enrollment target for the Phase 3 FORTIFY study of BBP-418 in LGMD2I/R9, with interim top-line results expected in 2025. The company expects to complete enrollment in its three Phase 3 programs by the end of 2024 and reports three readouts expected in 2025.
02—Key points
Key Highlights
- Revenue reached $213.3 million for the six months ended June 30, 2024, up from $3.5 million a year earlier, driven by $202.9 million of upfront payments and services revenue from the Bayer and Kyowa Kirin collaborations.
- Net loss attributable to common stockholders narrowed to $73.5 million ($0.39 per share) for the quarter, versus $157.9 million ($0.98 per share) in the prior-year quarter, aided by a $126.3 million gain on deconsolidation of a subsidiary.
- Cash, cash equivalents, marketable securities and short-term restricted cash rose to $587.2 million at June 30, 2024, from $392.6 million at December 31, 2023.
- The company refinanced its prior senior secured term loan, with $473.4 million in aggregate repayment, prepayment fees and exit costs, using $434.0 million of net proceeds from a new Blue Owl term loan.
- Operating costs rose to $177.7 million in the quarter from $147.7 million, mainly from higher SG&A to support commercialization readiness for acoramidis and higher R&D spending.
- The NDA for acoramidis in ATTR-CM has a PDUFA date of November 29, 2024, and the company is preparing for commercial launch.
- Low-dose infigratinib in achondroplasia (PROPEL 2 Cohort 5) showed a statistically significant increase in annualized height velocity of +2.50 cm/yr at Month 18, with the company citing a first-reported statistically significant improvement in body proportionality.
03—Questions
Frequently Asked Questions
What drove the increase in BridgeBio's revenue in the first half of 2024?
Revenue for the six months ended June 30, 2024 was $213.3 million, an increase of $209.8 million from the prior year. The filing attributes $202.9 million to recognition of non-refundable upfront payments and service revenue under the exclusive license and collaboration agreements with Bayer and Kyowa Kirin.
Why did the net loss decline compared with the prior year?
The net loss attributable to common stockholders was $73.5 million for the quarter versus $157.9 million a year earlier. Total other income was $100.0 million in the quarter, primarily due to a $126.3 million gain on deconsolidation of a subsidiary, partly offset by a $7.9 million net loss from an equity method investment and higher interest expense, while operating costs also increased.
How did BridgeBio's cash position change during the first half of 2024?
Cash, cash equivalents, marketable securities and short-term restricted cash totaled $587.2 million at June 30, 2024, compared with $392.6 million at December 31, 2023. The increase was mainly due to $434.0 million of net term loan proceeds and $314.8 million of net proceeds from equity financings, offset by $473.4 million for refinancing the prior term loan and $144.8 million of net cash used in operating activities.
What are the key near-term regulatory and clinical milestones?
The NDA for acoramidis for ATTR-CM has a PDUFA date of November 29, 2024. The company expects to complete enrollment in its three Phase 3 programs (encaleret, BBP-418 and low-dose infigratinib for achondroplasia) by the end of 2024, and it expects three readouts in 2025, including interim top-line results from FORTIFY in 2025 and topline data from CALIBRATE in 2025.
Could BridgeBio receive a Priority Review Voucher?
The filing states that BridgeBio may qualify for a Priority Review Voucher if BBP-418 is approved, since it has Rare Pediatric Disease Designation for LGMD2I/R9. Infigratinib for achondroplasia has received Fast Track Designation and Rare Pediatric Drug Designation, and the company may also qualify for a voucher if infigratinib is approved.
04—Continue